22 de agosto de 2019
22 de julio de 2010

Kowa Announces Successful EU Regulatory Application for Pitavastatin (y 2)

1) F Peter Guengerich; Cytochrome P450 and Chemical Toxicology.
Chem.Res.Toxicol.2008, 21, 70-83
2) Budinski D, Arneson V, Hounslow N, et al., Pitavastatin compared
with atorvastatin in primary hypercholesterolemia or combined
dyslipidemia Clinical Lipidology 2009,4;3:291-302
3) Budinski D, Arneson V, Hounslow N, et al., Comparison of
pitavastatin with simvastatin in primary hypercholesterolaemia or
combined dyslipidaemia Current Medical Research and Opinion
4) Stender S, Hounslow N. Robust efficacy of pitavastatin and
comparable safety to pravastatin. Atherosclerosis Suppl. 2009, Vol. 10,
Issue 2
5) Data on file (304,309).
6) Ose L, Budinski D, Hounslow N, Arneson V: Long-term treatment
with pitavastatin is effective and well tolerated by patients with
primary hypercholesterolemia or combined dyslipidemia. Atherosclerosis
2010; 202-208

Dr Rod Coombs, European Marketing Manager, Mobile: +44(0)7824-415025, Direct Line: +44(0)118-922-9013, E Mail: rcoombs@kowa.co.uk